Sanford C. Bernstein set a €105.00 ($122.09) target price on Merck KGaA (FRA:MRK) in a research note released on Monday morning. The firm currently has a buy rating on the healthcare company’s stock.

Other equities research analysts also recently issued reports about the company. Credit Suisse Group set a €93.00 ($108.14) price objective on Merck KGaA and gave the company a neutral rating in a report on Wednesday, August 8th. JPMorgan Chase & Co. set a €90.00 ($104.65) price objective on Merck KGaA and gave the company a neutral rating in a report on Wednesday, July 25th. Kepler Capital Markets set a €106.00 ($123.26) price objective on Merck KGaA and gave the company a buy rating in a report on Wednesday, September 12th. Independent Research set a €91.00 ($105.81) price objective on Merck KGaA and gave the company a neutral rating in a report on Thursday, August 9th. Finally, UBS Group set a €115.00 ($133.72) price objective on Merck KGaA and gave the company a buy rating in a report on Thursday, August 9th. Two research analysts have rated the stock with a sell rating, eleven have given a hold rating and seven have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of Hold and a consensus target price of €98.89 ($114.99).

Get Merck KGaA alerts:

FRA MRK opened at €97.58 ($113.47) on Monday. Merck KGaA has a 1-year low of €76.60 ($89.07) and a 1-year high of €115.00 ($133.72).

About Merck KGaA

MERCK Kommanditgesellschaft auf Aktien, a science and technology company, operates in the healthcare, life science, and performance materials sectors worldwide. The company offers prescription medicines to treat infertility, growth hormone deficiencies, type 2 diabetes, cardiovascular and thyroid diseases, multiple sclerosis, colorectal cancer, as well as carcinoma of the head and neck; diagnostics and prescription drugs for allergen immunotherapy; and fertility treatments.